We came across a bullish thesis on Viking Therapeutics, Inc. (VKTX) on Substack by Kontra Investments. In this article, we ...

Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug ...

Viking advances VK2735 with a phase 2a study targeting results in H2'25. Phase 3 begins in Q2'25, fueling progress and ...

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where ...

Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics, regardless of buyout speculations.

Ascletis Pharma's oral GLP-1 drug ASC30 shows 6.2% placebo-adjusted weight loss in Phase 1b obesity trial, matching Roche's ...

As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

Maine state officials on Tuesday reported new cases of bird flu in wild birds and urged precautions to protect chickens and other domestic birds. Avian influenza has been detected in "four Canada ...

We recently published an article titled These 10 Companies Led Monday’s Downturn. In this article, we are going to take a ...

Riley noted that it was especially impressed by the strong results from its potential weight loss asset VK2735, which could potentially become a groundbreaking development in the field.

When you’re craving something sweet, donuts are the perfect treat. However, you may want to stick to Dunkin' or Krispy Kreme. On January 7, the U.S. Food and Drug Administration (FDA) declared a class ...

And what's attracted a lot of attention over the past year is Viking's weight-loss drug program. The company is developing ...